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 Abstract
 Objective:  To evaluate the effects of weight loss on endocannabinoids, cardiometabolic and 
psychological parameters, eating disorders (ED) as well as quality of life (QoL) and to elucidate 
the role of endocannabinoids in metabolic syndrome (MS).  Methods:  In total, 114 patients 
with obesity were prospectively included in a 12-month weight loss program. Plasma endo-
cannabinoids were measured by mass spectrometry; ED, psychological and QoL-related pa-
rameters were evaluated by self-reported questionnaires; physical activity was measured by 
accelerometer. Nutritional assessment was done by a 3-day food diary.  Results: Among com-
pleters (n = 87), body weight decreased in 35 patients (–9.1 ± 8.6 kg), remained stable in 39 
patients, and increased in 13 patients (+5.8 ± 3.4 kg). 75% of patients with MS at baseline were 
free of MS at follow-up, and their baseline plasma N-palmitoylethanolamide (PEA) values were 
significantly lower when compared to patients with persisting MS. At baseline, there was a 
positive relationship between PEA and waist circumference (p = 0.005, R 2  = 0.08), fasting glu-
cose (p < 0.0001, R 2  = 0.12), total cholesterol (p = 0.001, R 2  = 0.11), triglycerides (p = 0.001, 
R 2  = 0.11), LDL-cholesterol (p = 0.03, R 2  = 0.05) as well as depression score (p = 0.002, R 2  = 
0.29).  Conclusion:  Plasma PEA might play a role in metabolic improvement after weight loss. 
Even in subjects without weight loss, a multidisciplinary intervention improves psychological 
outcomes, ED, and QoL.  © 2018 The Author(s)
 Published by S. Karger GmbH, Freiburg
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 Introduction
 Numerous conservative weight loss programs for obese patients have been described. 
Despite significant improvements of metabolic and cardiovascular outcomes, even after 
moderate or modest weight loss, the implementation of these programs into clinical practice 
seems to be difficult and subject to a substantial attrition rate. The complexity of interven-
tions, limited weight loss, and the relapse could be the main reasons for the failure of imple-
mentation of a non-surgical weight loss program. 
 A commonly recommended weight loss by lifestyle intervention in people with obesity is 
5–10% reduction in baseline weight  [1] . It has been well documented that moderate weight 
loss has an important impact on the onset and progression of type 2 diabetes and related 
co-morbidities, lipid disorders as well as hypertension, and could be cost-effective  [2–5] . In 
the Diabetes Prevention Program (DPP), a mean weight loss of 5.6 kg at 2.8 years resulted in 
a 58% relative reduction in the risk of type 2 diabetes  [2] . Recently, Magkos et al.  [5] have 
shown that a 5% weight loss was associated with significant improvement of body compo-
sition and multiple cardiometabolic risk factors as well as an improvement of insulin sensi-
tivity and overall β-cell function. Further weight loss is related to stepwise reduction of 
cardiometabolic risk factors in the majority of studies. 
 In both clinical and research settings, it is much easier to achieve and maintain a smaller 
extent of weight loss. However, most patients regain weight due to decrease of motivation 
and adherence both to diet and physical activity prescriptions, after only several months.
 On the other hand, the improvement of the psychosocial well-being of an obese subject 
after a modest weight loss is often underestimated. Furthermore, psychological disorders 
associated with obesity can be reduced and quality of life (QoL) improved by lifestyle changes 
even in the absence of weight loss  [6, 7] . It is matter of fact that overweight and obesity have 
a major and negative impact on mood, QoL, self-esteem, and self-confidence, which, in turn, 
negatively influence the social life and integration of the patient in the society and generate 
additional costs. Surprisingly, only a limited number of lifestyle intervention studies has 
incorporated self-reported psychological measures of well-being and QoL related to obesity. 
Lifestyle interventional programs are mainly focusing on weight modifications and metabolic 
improvements. 
 The endocannabinoids play an important role in the control of food intake, energy 
balance, and reward mechanisms  [8–10] . We have recently shown that plasma N-palmitoyle-
thanolamide (PEA) is correlated with coronary function which could be a functional precursor 
of coronary heart disease in obesity  [11] . Data on the relationship between plasma endocan-
nabinoids on one side and metabolic syndrome (MS) or depression on the other side are 
missing, and the role of endocannabinoids in the evolution of health-related outcomes is 
poorly understood. 
 Our aim was to evaluate the impact of a multidisciplinary and structured non-dieting 
weight loss program on metabolic and psychological parameters, eating disorders (ED), and 
QoL in obese primary care patients. We further evaluate the relationship between plasma endo-
cannabinoids and the evolution of weight, cardiometabolic and psychological parameters. 
 Subjects and Methods
 Studied Population
 A total number of 114 patients with obesity have been prospectively recruited at the University Hospitals 
of Geneva, Service of Therapeutic Education for Chronic Diseases, after their signed the written consent. The 
study protocol was approved by the local ethical committee. 
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 At baseline, 95 women (age 45.6 ± 10.5 years, BMI 37.0 ± 5.7 kg/m 2 ) and 19 men (age 45.8 ± 9.9 years, 
BMI 38.8 ± 4.6 kg/m 2 ) who fulfilled the study inclusion criteria agreed to participate in the study. Inclusion 
criteria were based on the presence of overweight or obesity in patients addressed for a weight loss program 
in the Service of Therapeutic Patient Education for Chronic Diseases, University Hospitals of Geneva. 
 Multidisciplinary Weight Loss Program
 The Service of Therapeutic Education for Chronic Diseases is a WHO collaborating and reference center 
for chronic disease management, particularly engaged in therapeutic patient education in the field of obesity 
and diabetes. The evaluated lifestyle intervention for weight loss is a multidisciplinary and structured patient 
educational program for obese patients over 12 months, with a minimum of 9 group sessions and 10 indi-
vidual outpatient appointments during the program duration. Each group session, of whole day duration 
(from 9 a.m. to 5 p.m.) consists of several workshops having a specific structure, depending on the topic (e.g., 
diet, eating behavior, physical activity).
 At the beginning of the program, patients are required  to participate in a predefined curriculum including 
on medical issues, balanced diet, cognitive-behavioral therapy, physical activity, and art therapy over 4 
consecutive days. During these 4 days, every patient has individual appointments with different healthcare 
providers (HCP) and specialists (e.g., physician, nurse, dietician, and psychologist) for medical, nutritional and 
psychological assessment on an interdisciplinary basis. Moreover, group sessions take place and are managed 
by the HCP according to the workshop’s topic. This 4-day (full time) educational program is followed by a 
coaching that takes place over the following 12 months. During this period, every patient participates in a 
minimum of 4 ambulatory, motivational and educational group sessions (every 2–3 months), each with 
different topic (i.e., diet, cognitive-behavioral therapy, physical activity, and body image) taking 1 day each. 
 A personal coach (i.e., an HCP specialized in both obesity management and patient education) is 
attributed to every patient. The patient has a follow-up on regular monthly basis with this HCP and during 
the 12-month follow-up period. His/her body weight is measured monthly during each 60-min individual 
appointment. During these face-to-face meetings, different aspects of healthy nutrition and physical activity 
are discussed with the patient, as well as the difficulties related to psychological and environmental issues 
(e.g., family, work, social live). The face-to-face meetings are individually tailored and are based on motiva-
tional interviewing  [12, 13] , and any diet or physical activity prescription is proposed to the patient. 
 At the end of the 12-month period, patients are required to participate in the last workshop day centered 
on results after 12 months. In addition to biological evaluation (e.g., fasting glucose, HbA1c, lipids, liver 
parameters, and blood pressure), group sessions and individual appointments take place during the day in 
order to assess the psychosocial well-being and QoL of every participant. 
 According to the study protocol, blood samples and questionnaires were collected at baseline and after 
12 months of the weight loss program.
 Biological and Laboratory Measurements
 Body weight, % body fat and fat-free mass were evaluated by the TANITA ®  bioimpedance scale (Tanita 
International Division, Yiewsley, UK).
 Total cholesterol, high-density lipoprotein cholesterol (HDL-cholesterol) and triglycerides were 
measured by Roche enzymatic colorimetric methods for modular systems (Hoffmann La-Roche Ltd, Basel, 
Switzerland). Low-density lipoprotein cholesterol (LDL-cholesterol) concentration was calculated by the 
Friedewald formula  [14] . Glucose, HbA1c, ASAT, ALAT, GGT and high-sensitivity-C-reactive protein (hs-CRP) 
were routinely measured.
 MS was defined according to the International Diabetes Federation (IDF) Guidelines for the Diagnosis 
of the Metabolic Syndrome  [15] . Namely, fasting glucose  ≥ 5.6 mmol/l, fasting triglycerides  ≥ 1.7 mmol/l, 
HDL cholesterol < 1.03 in men and < 1.29 mmol/l in women, and blood pressure  ≥ 130/85 mm Hg. Waist 
circumference was pathological in all subjects as was expected with respect to the population studied. 
 Endocannabinoid Measurement
 Plasma levels of N-arachidonoylethanolamide (AEA), 2-arachidonoylglycerol (2-AG), N-oleoylethanol-
amide (OEA),PEA were determined from peripheral arm vein blood samples. AEA, 2-AG, OEA, and PEA were 
extracted from 100 μl of plasma by liquid-liquid extraction and separated by liquid chromatography (Ultimate 
3000 RS; Dionex, Sunnyvale, CA, USA). Analyses were performed on a 5500 QTrap (triple quadrupole/linear 
ion trap) mass spectrometer equipped with a TurboIon-Spray TM  interface (AB Sciex, Concord, ON, Canada) 
 [16] .
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 Blood Pressure and Heart Rate Assessment
 Sitting blood pressure and heart rate are the mean values of three measurements (OMRON 705 cp, 
OMRON Healthcare Europe, Hoofddorp, The Netherlands).
 Basal Metabolic Rate Measurement
 Basal metabolic rate was measured by using indirect calorimetry method (Deltatrac-Ohmeda; Datex, 
Duisburg, Germany). Prior to each test, the analyzer was calibrated. Patients rested for at least 30 min before 
data were collected. Energy expenditure was calculated using the Weir equation with an algorithm provided 
by the manufacturer  [17] . 
 Nutritional Assessment
 Both at baseline and after 12 months, the patients filled in a 3-day paper food diary, including 2 week 
days and 1 weekend day. The daily caloric intake and diet composition were calculated with the Prodi ®  
software, version 5 (Nutri-Science GmbH, Hausach, Germany). 
 We calculated the ratio energy intake/basal metabolic rate to identify misreporting. Values of the ratio 
lower than 1.35 were recognized as underreporting  [18] . 
 Assessment of Physical Activity
 Physical activity was measured by a small single-axis accelerometer (Actigraph, AM7164–2.2; Computer 
Science and Applications, Pensacola, FL, USA)  [19, 20] . The acceleration signal was digitized with 10 
samples/s, registered as counts over 1-min intervals. The accelerometer was worn for up to 4 days on a belt 
in the small of the back, from waking to bedtime except during water-based activities. We analyzed partici-
pants with at least 3 days of data, including days when the device was worn more than 10 h; we assumed it 
was not worn if there were 60 consecutive minutes with no counts. Data were checked for spurious recording: 
high counts > 20,000 counts/min or repeated counts  [21] . Daily physical activity was calculated as average 
number of counts/min when accelerometer was worn.
 Evaluation of Depression and Anxiety by Self-Questionnaires 
 Beck Depression Inventory (BDI-II)
 We used the French translation  [22] of the original BDI-II questionnaire  [23] for measuring the severity 
of depression. The questionnaire is composed of 21 items relating to depression symptoms such as hope-
lessness and irritability, cognitions such as guilt or feelings of being punished as well as physical symptoms 
such as fatigue, weight loss, and lack of interest in sex. The cut-offs used are: <10: normal score, 10–18: mild 
depression, 19–29: moderate depression, and >30: severe depression  [24] . 
 Hospital Anxiety and Depression Scale (HAD)
 This self-assessment scale has been developed and found to be a reliable instrument for detecting states 
of depression and anxiety in the setting of a hospital medical outpatient clinic  [25] . It is composed of 14 items, 
with 7 items evaluating the anxiety and the 7 other items evaluating the depression. The cut-offs used are: 
≤ 7: no anxiety or depression, 8–10: some elements for, or  ≥ 11: many elements for anxiety or depression.
 Eating Disorders Evaluation
 To examine pathological eating habits and the psychopathology around them, we used the French 
version of the Eating Disorder Examination Questionnaire (EDE-Q)  [26] . The EDE-Q encompasses four 
subscales ( Restraint ,  Eating Concern ,  Shape Concern, and Weight Concern)  and a global score for symptoms 
and behaviors within the past 28 days.  The possible values between 0 and 6 indicated no ED symptoms in 
the lower end of the range and distinct ED pathology in the higher end. 
 The Three-Factor Eating Questionnaire (TFEQ)  [27] was used to complete eating behavior evaluation. 
The TFEQ is based on 51 items measuring the following dimensions: cognitive restraint of eating (factor I, 21 
items), disinhibition (factor II, 16 items), and hunger (factor III, 14 items). Each item scores either 0 or 1 
point. The minimum score for factors I-II-III is therefore 0-0-0, the possible maximum score 21-16-14.
 QoL Assessment
 The QoL was evaluated by the Impact of Weight on QoL (IWQOL-Lite © ) questionnaire  [28] , a 31-item 
questionnaire evaluating social, professional and sexual life, self-esteem, and mobility. Higher scores are sign 
of a better QoL in the domain evaluated. 
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 Statistical Analysis
 At the end of the follow-up (12 months),patients were assigned to 1 of 3 following groups according to 
body weight evolution: weight loss group (patients who lost > 2.5% of initial body weight); weight-stable 
group (body weight variations ± 2.5%); and weight gain group (patients who showed an increase of >2.5% 
of initial body weight). Patient characteristics were compared using the ANOVA (parametric data) followed 
by Fischer post-hoc test analysis or the Kruskal-Wallis test by ranks (non-parametric data).
 Relationships between different parameters were evaluated by simple and multiple regression analysis. 
ANOVA for repeated measurements was used to investigate the modifications occurring after the inter-
vention. The differences in percent prevalence of metabolic normality were evaluated by chi-square test. 
Univariate and multivariate logistic regression analysis was used to establish predictive factors of weight loss 
evolution.
 Results are expressed as mean ± SD. All statistical analyses were performed with the STATA software 
(v. 10; Stata Corporation, College Station, TX, USA). The alpha was set at 0.05 (two-sided).
 Results
 Program Attendance
 From the total cohort of 114 patients, 87 patients (76.3%) have completed the follow-up 
at the end of the program. Among completers, 35 patients (40%) lost weight (–9.1 ± 8.6 kg; 
–8.2%), 39 patients (45%) presented stable weight (–0.2 ± 1.4 kg; –0.2%), and 13 patients 
(15%) increased their body weight (+5.8 ± 3.4 kg; +5.8%). The anthropometric and cardio-
metabolic characteristics of the subjects according to body weight evolution at 12 months are 
presented in  table 1 . No statistically significant differences between the 3 groups in terms of 
baseline characteristics were observed. 
 The drop-out rate was 23.7%, with 27 subjects who have decided to interrupt the follow-
up before the end of the program. 24 of them were successfully contacted after the end of the 
program. Among the contacted subjects, 16 had lost weight (mean weight loss 13.9 ± 11.9 kg; 
7 of them had undergone Roux-en-Y gastric bypass) and 1 patient had stable weight. Five 
patients gained weight (mean weight gain 6.0 ± 2.9 kg). Two patients did not want to share 
their last value of body weight with the HCP since they had stopped the program. 
 Weight Loss Group
 Among subjects with weight loss (n = 35), patients lost mainly fat mass (–7.9 ± 8.0 kg; 
p < 0.001) and reduced waist circumference (–7.8 ± 7.5 cm; p < 0.001). The decrease in lean 
body mass was low (–1.22 ± 2.96 kg; p = 0.02). The systolic blood pressure significantly 
decreased (–5.1 ± 14.5 mm Hg; p = 0.04).
 Among laboratory parameters, we observed a significant decrease in fasting plasma 
glucose (baseline: 5.8 ± 1.0 mmol/l, after 12 months: 5.3 ± 0.7 mmol/l; p = 0.002) and ALAT 
(baseline: 30.3 ± 21.1 U/l, after 12 months: 22.3 ± 9.7 U/l; p = 0.04). No significant differences 
with regard to ASAT, GGT, plasma lipids, or hs-CRP have been observed between baseline and 
12-month follow-up. 
 With respect to endocannabinoids, we observed a statistically significant decrease of 
2-AG (baseline: 13.7 ± 11.4 ng/ml, after 12 months: 6.9 ± 4.5 ng/ml;, p = 0.02). There was a 
tendency to reduction of OEA and PEA levels without reaching statistically significant differ-
ences (p = 0.08 for both). No changes of AEA have been observed. 
 The weight loss group became physically more active during the weight loss program 
(baseline: 244 ± 124 counts/day, after 12 months: 279 ± 102 counts/day; p = 0.01) and 
slightly, but statistically significantly increased the percent protein intake (baseline: 17.4 ± 
4.0%, after 12 months: 18.9 ± 4.9%; p = 0.03) ( table 2 ).
149Obes Facts 2018;11:144–156
 DOI: 10.1159/000487890 
 Pataky et al.: Effects of a Weight Loss Program on Metabolic Syndrome, Eating 
Disorders and Psychological Outcomes: Mediation by Endocannabinoids? 
www.karger.com/ofa
© 2017 The Author(s). Published by S. Karger GmbH, Freiburg
 Ta
bl
e 
1.
  A
nt
hr
op
om
et
ri
c 
an
d 
ca
rd
io
m
et
ab
ol
ic
 c
ha
ra
ct
er
is
ti
cs
 o
f s
ub
je
ct
s 
ac
co
rd
in
g 
to
 b
od
y 
w
ei
gh
t e
vo
lu
ti
on
 d
ur
in
g 
th
e 
1-
ye
ar
 w
ei
gh
t l
os
s 
pr
og
ra
m
W
ei
gh
t l
os
s 
> 
2.
5%
 in
 b
as
el
in
e 
w
ei
gh
t
(n
 =
 3
5)
W
ei
gh
t s
ta
bl
e 
± 
2.
5%
(n
 =
 3
9)
W
ei
gh
t g
ai
n 
> 
2.
5%
 in
 b
as
el
in
e 
w
ei
gh
t
  (
n 
= 
13
)
ba
se
lin
e
1 
ye
ar
p 
va
lu
e
ba
se
lin
e
1 
ye
ar
p 
va
lu
e
b a
se
lin
e
1 
ye
ar
p 
va
lu
e
A
ge
, y
ea
rs
46
 ±
 8
–
–
47
 ±
 1
1
–
–
46
 ±
 9
–
–
G
en
de
r,
 W
/M
28
/7
–
–
34
/5
–
–
11
/2
–
–
%
 W
ei
gh
t l
os
s
–
–8
.2
 ±
 5
.6
–
–
–0
.2
 ±
 1
.4
–
–
+5
.8
 ±
 2
.8
–
B
od
y 
w
ei
gh
t, 
kg
10
3.
4 
± 
22
.9
94
.3
 ±
 1
7.
8
<0
.0
01
10
1.
6 
± 
20
.6
10
1.
4 
± 
20
.8
0.
49
98
.8
 ±
 1
9.
7
10
4.
7 
± 
21
.5
<0
.0
01
B
M
I, 
kg
/m
2
37
.8
 ±
 6
.2
34
.5
 ±
 5
.1
<0
.0
01
37
.4
 ±
 6
.2
37
.4
 ±
 6
.3
0.
50
35
.8
 ±
 4
.3
37
.8
 ±
 4
.5
<0
.0
01
LB
M
, k
g
56
.7
 ±
 1
0.
3
54
.9
 ±
 9
.8
0.
02
54
.9
 ±
 1
0.
6
55
.0
 ±
 1
0.
4
0.
65
55
.2
 ±
 9
.6
55
.2
 ±
 9
.7
0.
80
FM
, k
g
47
.1
 ±
 1
5.
4
38
.9
 ±
 1
1.
6
<0
.0
01
47
.1
 ±
 1
3.
4
46
.1
 ±
 1
3.
2
0.
36
44
.3
 ±
 1
3.
2
48
.5
 ±
 1
4.
8
0.
03
W
ai
st
, c
m
11
4 
± 
16
10
7 
± 
14
<0
.0
01
11
3 
± 
11
11
3 
± 
15
0.
78
11
0 
± 
16
11
6 
± 
14
0.
02
SB
P,
 m
m
 H
g
12
3 
± 
14
11
8 
± 
15
0.
04
12
3 
± 
16
12
1 
± 
14
0.
39
12
8 
± 
14
12
5 
± 
14
0.
47
D
B
P,
 m
m
 H
g
82
 ±
 1
0
78
 ±
 1
3
0.
14
81
 ±
 9
80
 ±
 1
0
0.
28
86
 ±
 1
4
84
 ±
 1
0
0.
23
H
R
, b
pm
6 9
 ±
 8
67
 ±
 1
0
0.
11
68
 ±
 1
0
68
 ±
 1
1
0.
69
72
 ±
 1
1
69
 ±
 1
3
0.
07
Fa
st
in
g 
gl
uc
os
e,
 m
m
ol
/l
5.
8 
± 
1.
0
5.
3 
± 
0.
7
0.
00
2
5.
9 
± 
1.
3
5.
6 
± 
0.
8
0.
42
5.
7 
± 
0.
7
5.
8 
± 
1.
1
0.
52
H
bA
1c
, %
5.
4 
± 
0.
4
5.
4 
± 
0.
4
0.
71
5.
5 
± 
0.
6
5.
5 
± 
0.
5
0.
56
5.
5 
± 
0.
3
5.
8 
± 
1.
0
0.
61
T
ot
. c
ho
le
st
er
ol
, m
m
ol
/l
5.
1 
± 
0.
9
5.
1 
± 
0.
8
0.
45
5.
4 
± 
1.
0
5.
5 
± 
0.
9
0.
51
5.
2 
± 
1.
2
5.
6 
± 
1.
1
0.
17
LD
L-
ch
ol
es
te
ro
l, 
m
m
ol
/l
3.
2 
± 
0.
8
3.
2 
± 
0.
6
0.
28
3.
4 
± 
0.
8
3.
5 
± 
0.
9
0.
12
3.
2 
± 
1.
1
3.
5 
± 
0.
9
0.
06
H
D
L-
ch
ol
es
te
ro
l, 
m
m
ol
/l
1.
3 
± 
0.
3
1.
4 
± 
0.
3
0.
12
1.
3 
± 
0.
4
1.
4 
± 
0.
3
0.
75
1.
4 
± 
0.
3
1.
4 
± 
0.
2
0.
57
T
G
, m
m
ol
/l
1.
4 
± 
0.
8
1.
3 
± 
1.
0
0.
08
1.
7 
± 
1.
2
1.
5 
± 
1.
0
0.
18
1.
4 
± 
0.
5
1.
6 
± 
1.
0
0.
49
A
LA
T
, U
/l
30
.3
 ±
 2
1.
1
22
.3
 ±
 9
.7
0.
04
30
.7
 ±
 1
4.
2
28
.9
 ±
 1
3.
8
0.
77
25
.6
 ±
 1
1.
0
33
.3
 ±
 1
7.
4
0.
24
A
SA
T
, U
/l
23
.7
 ±
 2
6.
2
18
.7
 ±
 8
.5
0.
27
20
.2
 ±
 5
.3
21
.1
 ±
 5
.9
0.
06
17
.6
 ±
 4
.7
23
.3
 ±
 9
.3
0.
10
G
G
T
, U
/l
55
.3
 ±
 1
2.
6
35
.0
 ±
 7
8.
3
0.
06
29
.2
 ±
 2
1.
5
26
.8
 ±
 2
1.
5
0.
92
23
.7
 ±
 2
1.
0
16
.5
 ±
 1
4.
5
0.
23
hs
-C
R
P,
 m
g/
l
8.
5 
± 
10
.9
8.
1 
± 
13
.1
0.
42
7.
4 
± 
8.
1
7.
9 
± 
7.
9
0.
11
6.
8 
± 
6.
1
10
.9
 ±
 1
0.
2
0.
16
A
E
A
, n
g/
m
l
0.
9 
± 
0.
4
0.
7 
± 
0.
3
0.
38
0.
8 
± 
0.
3
0.
7 
± 
0.
3
0.
90
0.
7 
± 
0.
3
1.
0 
± 
0.
3
0.
46
2-
A
G
, n
g/
m
l
13
.7
 ±
 1
1.
4
6.
9 
± 
4.
5
0.
02
15
.5
 ±
 1
4.
6
10
.3
 ±
 8
.7
0.
12
21
.8
 ±
 3
0.
6
8.
4 
± 
4.
1
0.
28
O
E
A
, n
g/
m
l
4.
0 
± 
1.
5
3.
0 
± 
1.
2
0.
08
3.
4 
± 
1.
0
3.
1 
± 
1.
0
0.
39
3.
3 
± 
1.
0
4.
0 
± 
1.
0
0.
63
PE
A
, n
g/
m
l
3.
4 
± 
1.
0
2.
8 
± 
0.
8
0.
08
3.
2 
± 
0.
7
2.
9 
± 
0.
7
0.
21
3.
2 
± 
0.
8
3.
6 
± 
0.
7
0.
95
 LB
M
 =
 L
ea
n 
bo
dy
 m
as
s;
 F
M
 =
 fa
t m
as
s;
 S
B
P 
= 
sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e;
 D
B
P 
= 
di
as
to
lic
 b
lo
od
 p
re
ss
ur
e;
 H
R
 =
 h
ea
rt
 r
at
e;
 L
D
L 
= 
lo
w
-d
en
si
ty
 c
ho
le
st
er
ol
; H
D
L 
= 
hi
gh
-d
en
si
ty
 
ch
ol
es
te
ro
l; 
T
G
 =
 tr
ig
ly
ce
ri
de
s;
 h
s-
CR
P 
= 
hi
gh
-s
en
si
ti
vi
ty
 C
-r
ea
ct
iv
e 
pr
ot
ei
n;
 A
E
A
 =
 N
-a
ra
ch
id
on
oy
le
th
an
ol
am
id
e;
 2
-A
G
 =
 2
-a
ra
ch
id
on
oy
lg
ly
ce
ro
l; 
O
E
A
 =
 N
-o
le
oy
le
th
an
ol
-
am
id
e;
 P
E
A
 =
 N
-p
al
m
it
oy
le
th
an
ol
am
id
e.
150Obes Facts 2018;11:144–156
 DOI: 10.1159/000487890 
 Pataky et al.: Effects of a Weight Loss Program on Metabolic Syndrome, Eating 
Disorders and Psychological Outcomes: Mediation by Endocannabinoids? 
www.karger.com/ofa
© 2018 The Author(s). Published by S. Karger GmbH, Freiburg
 Ta
bl
e 
2.
  P
hy
si
ca
l a
ct
iv
it
y 
an
d 
di
et
ar
y 
re
co
rd
s 
of
 s
ub
je
ct
s 
ac
co
rd
in
g 
to
 b
od
y 
w
ei
gh
t e
vo
lu
ti
on
 d
ur
in
g 
th
e 
1-
ye
ar
 w
ei
gh
t l
os
s 
pr
og
ra
m
W
ei
gh
t l
os
s 
> 
2.
5%
 in
 b
as
el
in
e 
w
ei
gh
t
(n
 =
 3
5)
W
ei
gh
t s
ta
bl
e 
± 
2.
5%
(n
 =
 3
9)
W
ei
gh
t g
ai
n 
> 
2.
5%
 in
 b
as
el
in
e 
w
ei
gh
t
 (n
 =
 1
3)
ba
se
lin
e
1 
ye
ar
p 
va
lu
e
ba
se
lin
e
1 
ye
ar
p 
va
lu
e
ba
 se
lin
e
1 
ye
ar
p 
va
lu
e
T
ot
al
 c
ou
nt
/d
ay
24
4 
± 
12
4
27
9 
± 
10
2
0.
01
23
5 
± 
96
23
9 
± 
11
7
0.
38
29
0 
± 
59
25
2 
± 
11
0.
64
T
ot
al
 e
ne
rg
y 
in
ta
ke
, k
ca
l/
da
y
1,
80
4 
± 
48
6
1,
90
6 
± 
40
9
0.
93
1,
99
5 
± 
56
4
1,
83
8 
± 
55
8
0.
06
2,
06
1 
± 
44
2
1,
85
7 
± 
89
4
0.
46
Pr
ot
ei
ns
, %
17
.4
 ±
 4
.0
18
.9
 ±
 4
.9
0.
02
17
.3
 ±
 4
.3
17
.8
 ±
 3
.4
0.
21
16
.6
 ±
 5
.4
17
.8
 ±
 5
.4
0.
84
Li
pi
ds
, %
40
.4
 ±
 7
.3
39
.9
 ±
 7
.3
0.
96
37
.8
 ±
 7
.5
38
.2
 ±
 8
.2
0.
98
40
.7
 ±
 7
.6
39
.3
 ±
 5
.3
0.
36
Ca
rb
oh
yd
ra
te
s,
 %
40
.5
 ±
 8
.9
39
.5
 ±
 1
0.
5
0.
44
42
.7
 ±
 8
.7
42
.4
 ±
 8
.0
0.
99
41
.8
 ±
 8
.9
41
.0
 ±
 8
.1
0.
40
 T
ot
al
 c
ou
nt
/d
ay
 =
– 
Su
m
 o
f t
ot
al
 a
ct
iv
it
y 
co
un
ts
/m
in
 a
cc
um
ul
at
ed
 in
 a
 d
ay
. D
ai
ly
 p
hy
si
ca
l a
ct
iv
it
y 
w
as
 c
al
cu
la
te
d 
as
 a
ve
ra
ge
 n
um
be
r 
of
 c
ou
nt
s/
m
in
 w
he
n 
ac
ce
le
ro
m
et
er
 
w
as
 w
or
n.
 Ta
bl
e 
3.
  P
sy
ch
ol
og
ic
al
 c
ha
ra
ct
er
is
ti
cs
, e
at
in
g 
di
so
rd
er
s 
an
d 
qu
al
it
y 
of
 li
fe
 o
f s
ub
je
ct
s 
ac
co
rd
in
g 
to
 b
od
y 
w
ei
gh
t e
vo
lu
ti
on
 d
ur
in
g 
th
e 
1-
ye
ar
 w
ei
gh
t l
os
s 
pr
og
ra
m
W
ei
gh
t l
os
s 
> 
2.
5%
 in
 b
as
el
in
e 
w
ei
gh
t
(n
 =
 3
5)
W
ei
gh
t s
ta
bl
e 
± 
2.
5%
(n
 =
 3
9)
W
ei
gh
t g
ai
n 
> 
2.
5%
 in
 b
as
el
in
e 
w
ei
gh
t
 (n
 =
 1
3)
ba
se
lin
e
1 
ye
ar
p 
va
lu
e
ba
se
lin
e
1 
ye
ar
p 
va
lu
e
ba
 se
lin
e
1 
ye
ar
p 
va
lu
e
D
ep
re
ss
io
n 
(B
D
I-
II
)
17
.8
 ±
 1
1.
0
12
.3
 ±
 1
0.
8
0.
00
2
17
.5
 ±
 1
2.
8
15
.9
 ±
 1
4.
5
0.
50
15
.8
 ±
 1
1.
0
12
.2
 ±
 1
0.
3
0.
45
D
ep
re
ss
io
n 
(H
A
D
)
7.
1 
± 
4.
0
4.
6 
± 
3.
5
<0
.0
01
7.
5 
± 
4.
8
5.
0 
± 
4.
2
<0
.0
01
6.
4 
± 
5.
0
6.
7 
± 
3.
8
0.
84
A
nx
ie
ty
 (
H
A
D
)
8.
3 
± 
3.
8
8.
1 
± 
4.
5
0.
44
8.
6 
± 
4.
5
8.
1 
± 
4.
1
0.
36
8.
3 
± 
3.
9
8.
6 
± 
3.
5
0.
81
D
ie
ta
ry
 R
es
tr
ai
nt
 (
T
FE
Q
)
6.
9 
± 
3.
4
11
.0
 ±
 3
.3
<0
.0
01
7.
8 
± 
5.
0
9.
0 
± 
4.
7
0.
02
8.
6 
± 
5.
2
9.
9 
± 
6.
4
0.
23
D
ie
ta
ry
 R
es
tr
ai
nt
 (
E
D
E
Q
)
1.
24
 ±
 1
.0
2
2.
28
 ±
 1
.2
2
0.
00
1
1.
49
 ±
 1
.3
6
1.
68
 ±
 1
.4
8
0.
35
1.
49
 ±
 1
.3
9
1.
68
 ±
 1
.4
3
0.
58
D
es
-i
nh
ib
it
io
n 
(T
FE
Q
)
8.
7 
± 
3.
5
7.
4 
± 
3.
0
0.
01
10
.0
 ±
 3
.2
8.
2 
± 
3.
0
<0
.0
01
9.
4 
± 
3.
3
9.
7 
± 
3.
5
0.
41
H
un
ge
r 
(T
FE
Q
)
5.
9 
± 
3.
8
4.
4 
± 
3.
0
0.
01
6.
4 
± 
3.
8
4.
4 
± 
2.
8
<0
.0
01
6.
5 
± 
4.
1
5.
2 
± 
3.
7
0.
25
E
at
in
g 
co
nc
er
n 
(E
D
E
Q
)
1.
48
 ±
 1
.4
6
0.
86
 ±
 1
.3
7
0.
02
1.
62
 ±
 1
.3
7
1.
15
 ±
 1
.2
3
0.
03
1.
35
 ±
 1
.5
3
1.
46
 ±
 1
.4
4
0.
73
Sh
ap
e 
co
nc
er
n 
(E
D
E
Q
)
4.
13
 ±
 1
.2
2
3.
03
 ±
 1
.5
3
<0
.0
01
3.
99
 ±
 1
.4
1
3.
49
 ±
 1
.6
4
0.
03
3.
82
 ±
 1
.5
1
3.
53
 ±
 1
.6
7
0.
28
W
ei
gh
t c
on
ce
rn
 (
E
D
E
Q
)
3.
56
 ±
 1
.1
3
2.
75
 ±
 1
.2
3
<0
.0
01
3.
50
 ±
 1
.1
7
2.
97
 ±
 1
.4
9
0.
01
3.
22
 ±
 1
.2
0
3.
03
 ±
 1
.3
3
0.
38
E
D
E
Q
 G
lo
ba
l s
co
re
2.
61
 ±
 0
.8
3
2.
27
 ±
 0
.9
5
<0
.0
01
2.
59
 ±
 1
.0
6
2.
32
 ±
 1
.0
6
0.
18
2.
48
 ±
 1
.0
7
2.
43
 ±
 1
.1
3
0.
79
So
ci
al
 li
fe
, %
71
.8
 ±
 2
3.
7
83
.3
 ±
 1
8.
0
<0
.0
01
75
.8
 ±
 2
4.
9
75
.0
 ±
 2
2.
0
0.
82
83
.5
 ±
 1
5.
3
79
.8
 ±
 1
9.
4
0.
38
Pr
of
es
si
on
al
 li
fe
, %
 
69
.9
 ±
 2
9.
4
83
.3
 ±
 1
8.
4
<0
.0
01
77
.8
 ±
 2
4.
8
79
.6
 ±
 2
3.
6
0.
62
82
.7
 ±
 1
7.
0
80
.4
 ±
 2
6.
3
0.
66
Se
xu
al
 li
fe
, %
 
60
.6
 ±
 3
2.
9
71
.1
 ±
 3
3.
4
0.
03
70
.3
 ±
 3
4.
4
77
.3
 ±
 3
0.
4
0.
26
69
.7
 ±
 2
9.
0
65
.3
 ±
 3
4.
6
0.
44
Se
lf
-e
st
ee
m
, %
 
43
.7
 ±
 2
7.
1
54
.1
 ±
 3
0.
9
0.
00
6
48
.1
 ±
 2
9.
9
56
.6
 ±
 2
9.
9
0.
02
42
.3
 ±
 2
5.
3
46
.0
 ±
 2
1.
2
0.
48
M
ob
ili
ty
, %
 
51
.9
 ±
 2
5.
4
67
.5
 ±
 2
2.
9
<0
.0
01
50
.1
 ±
 2
5.
0
58
.2
 ±
 2
3.
6
0.
01
60
.4
 ±
 1
9.
7
56
.8
 ±
 2
1.
4
0.
35
 B
D
I-
II
 =
 B
ec
k 
D
ep
re
ss
io
n 
In
ve
nt
or
y 
Q
ue
st
io
nn
ai
re
; H
A
D
 =
 H
os
pi
ta
l A
nx
ie
ty
 a
nd
 D
ep
re
ss
io
n 
Sc
al
e;
 T
FE
Q
 =
 T
hr
ee
-F
ac
to
r 
E
at
in
g 
Q
ue
st
io
nn
ai
re
; E
D
E
Q
 =
 E
at
in
g 
D
is
or
de
r 
E
xa
m
in
at
io
n 
Q
ue
st
io
nn
ai
re
.
151Obes Facts 2018;11:144–156
 DOI: 10.1159/000487890 
 Pataky et al.: Effects of a Weight Loss Program on Metabolic Syndrome, Eating 
Disorders and Psychological Outcomes: Mediation by Endocannabinoids? 
www.karger.com/ofa
© 2017 The Author(s). Published by S. Karger GmbH, Freiburg
 All psychological parameters, ED as well as QoL ( table 3 ) statistically significantly 
improved during the 12-month weight loss program, with the exception of anxiety score 
which did not change. The dietary restraint increased, as evaluated by both TFEQ and EDEQ 
questionnaires (p < 0.001 and p = 0.001, respectively). 
 Weight-Stable and Weight Gain Groups
 No changes in terms of body composition and laboratory parameters were observed in 
both weight-stable (n = 39) and weight gain (n = 13) groups, except for the increase in fat 
mass and waist circumference for the weight gain group ( table 1 ). 
 From the psychological point of view, we noticed statistically significant improvements 
among the weight-stable group ( table 3 ). Namely, the depression score (HAD) was lower 
(p < 0.001), ED improved (increase of dietary restraint (p = 0.02) as well as decrease of disin-
hibition (p < 0.001), hunger (p < 0.001), eating (p = 0.03), shape (p = 0.03) and weight concern 
(p = 0.01)). Different aspects of QoL such as self-esteem (p = 0.02) and mobility (p = 0.01) 
improved ( table 3 ) in the weight-stable group. 
 No changes in terms of psychological parameters, ED, or QoL were noticed among the 
weight gain group.
 Factors Related to Body Weight Evolution
 When analyzing in a univariate logistic regression model the following differences 
between baseline and 12-month follow-up (as expressed as delta values) were significantly 
associated with the weight loss at 12-month follow-up: increase of dietary restraint (OR 0.82 
(0.71–0.95); p = 0.009), mobility (OR 0.96 (0.93–0.99);, p = 0.01), social life (OR 0.96 (0.93–
0.9); p = 0.004) and decrease of shape concern (OR 1.66 (1.09–2.52); p = 0.02).
 In a multivariate logistic regression model, the increase of dietary restraint (OR 0.81 
(0.69–0.96);, p = 0.02) and decrease of shape concern (OR 1.68 (1.01–2.79),; p = 0.04) 
remained statistically significant.
 MS Evolution
 At baseline, 100 patients (87.7%) of the 114 patients presented with MS and 14 (12.3%) 
were MS-free according to IDF definition  [15] . 
 At 12-month follow-up, we missed some data for 6 subjects among the completers (n = 
87). Thus, the proportion of patients with or without MS was calculated in 81 patients. Among 
these completers, 61 patients (75.3%) became free of MS and 20 patients (24.7%) still 
presented with MS at 12 months. No patient has developed MS during the follow-up (p = 
0.032). The remission of MS was independent of body weight (p = 0.35).
 In subjects who became free of MS, we noticed significantly lower baseline PEA (3.3 ± 0.8 
ng/ml vs. 4.4 ± 1.3 ng/ml; p = 0.01), total daily energy intake (1,678 ± 475 vs. 2,213 ± 520 
kcal/day; p = 0.02), and amount of consumed saturated fatty acids (SFA) (26.3 ± 8.2 vs. 36.8 
± 16.5 g/day; p = 0.04), when compared with subjects who still showed MS at follow-up in the 
weight loss subgroup.
 Using a univariate logistic regression model, we identified baseline PEA to be related to 
MS remission (OR 2.20 (1.08–4.50); p = 0.03). 
 The changes of depression score (as expressed as delta values according to BDI-II) were 
significantly associated with the MS remission at 12 months (OR 1.10 (1.02–1.19); p = 0.01).
 Plasma Endocannabinoids
 When analyzing by simple regression analysis, we observed a positive relationship 
between baseline PEA and baseline waist circumference (p = 0.005, R 2  = 0.08), fasting glucose 
(p < 0.0001, R 2  = 0.12), total cholesterol (p = 0.001, R 2  = 0.11), triglycerides (p = 0.001, R 2  = 
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0.11) as well as LDL-cholesterol (p = 0.03, R 2  = 0.05). There was a positive relationship 
between baseline PEA and baseline depression score assessed by HAD questionnaire (p = 
0.002, R 2  = 0.29). There was no relationship between PEA and body weight or BMI.
 Discussion
 We have seen that the structured, multidisciplinary and patient-educational lifestyle 
weight loss program induced a weight reduction in 40% of participants at 12-month follow-
up. This weight loss, corresponding to 8.2% of baseline weight, resulted in significant 
improvement of cardiometabolic and psychological parameters, ED, and QoL ( tables 1–3 ). 
These results confirm previous observations reporting clinically meaningful health improve-
ments after a moderate weight loss  [29–31] . 
 In addition, our study clearly indicates that, even in the groups with absence of weight 
loss, an educational program exerts beneficial effects on patient’s QoL and also contributes to 
the improvement of several psychological parameters, namely those related to weight, body 
shape and eating concerns, reduction of both disinhibition and hunger feelings, and 
improvement of depression score ( table 3 ). Some aspects of QoL are also improved in the 
absence of weight loss. It is well known that all these psychological traits largely contribute 
to the development of pathological eating habits.
 Recently, a meta-analysis of 44 studies implementing DPP lifestyle interventions in US 
clinical settings published between 2005 and 2015 showed that, after a mean follow-up of 9.3 
months, the mean weight loss was 3.8 kg in intervention arms. This relatively modest weight 
reduction was associated with favorable changes in blood pressure, plasma cholesterol, and 
glucose  [29] . The analyzed studies retained the DPP’s core principles of calorie-restricted 
diets and 150 min of moderate-intensity exercise per week, and mainly group sessions were 
administrated. However, psychological or QoL-related characteristics were not assessed or 
reported. 
 Similarly, another meta-analysis assessing the effectiveness of lifestyle interventions (79 
studies, follow-up varying from 12 to 54 months) on glycemic indicators among adults 
without impaired glucose tolerance or diabetes showed a weight loss of 4.0 kg to be accom-
panied by improvement of both plasma glucose and insulin sensitivity  [30] .
 The MOVE! lifestyle change program showed a mean weight change of –2.8% and a 33% 
reduction of diabetes incidence among 238,000 veterans with 12-month data  [31] . 
 In our study, the mean weight loss was 9.1 kg (8.2%) in the weight loss group with signif-
icant improvements of blood pressure and fasting glucose after 12 months. Interestingly, but 
not surprisingly, patients who lost weight presented increase in dietary restriction and 
protein consumption during the program, became physically more active ( table 2 ), and 
improved their mood and eating disorders as well as QoL ( table 3 ). However, increase in 
dietary restraint score (evaluated by both TFEQ and EDEQ questionnaires) was not reflected 
by decrease of total daily caloric consumption, as assessed by food diary. Dietary record as 
used in the present study is based on self-reported dietary intake, which is liable to potential 
biases and often underestimates the energy intake  [32] , particularly at the beginning of a 
weight loss program. The underreporting of energy intake (related to measured total energy 
expenditure) in obese subjects could be as high as 25–50% of total calories  [18] . In our weight 
loss group, 77% of patients underreported their caloric consumption, with a mean difference 
between reported energy intake and measured basal metabolic rate of 125 kcal/day (data not 
shown). Roughly, the total body weight loss of 9.1 kg during 12 months represents a daily 
caloric deficit of 190 kcal. The absence of this caloric deficit (as documented by self-reported 
food diary) necessary to lose weight could be explained by the mentioned underreporting at 
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baseline on one side and the modest increase in physical activity at follow-up on the other 
side. 
 It has been shown that cognitive behavioral treatment including motivational inter-
viewing can help patients to support commitment to change and to address maladaptive 
thinking  [33, 34] . The weight loss program of our study offers both group sessions and indi-
vidual face-to-face appointments to patients during 1 year. The patient educational approach 
and behavioral therapy have been designed to provide obese patients with techniques for 
adopting dietary and physical activity recommendations on regular basis and without 
prescribing any kind of restrictive diet or intensive physical activity. Face-to-face appoint-
ments between the patient and his/her coach are encompassing also difficulties related to 
psychological and environmental issues (family, work and social life) in order to help patients 
with stress management and to avoid stress and/or personal problems’ compensations by 
food. 
 Traditional lifestyle interventions focusing on weight loss as primary outcome ignore 
evidence that dieting may have important impact on eating behavior and unhealthy attitudes 
 [35, 36] , thus contributing to cyclic weight regain in a large proportion of obese people with 
more pronounced psychological suffering as a consequence. The absence of psychological 
and QoL evaluation in lifestyle studies could lead to underestimation of the psychological 
suffering due to obesity itself and after different weight loss programs. 
 In our study we also assessed psychological well-being which was significantly improved 
in both the weight loss and the weight-stable group. Even in absence of weight loss, patients 
with stable weight have significantly improved depression score (HAD), eating disorders and 
QoL ( table 3 ). One could speculate that the patients who stabilized their weight may have 
prevented further weight gain during the 12 months. 
 In the whole population, 75% of subjects with MS at baseline improved their metabolic 
status and became free of MS at follow-up. When assessing the evolution of MS, we have seen 
that patients, who became free of MS at follow-up, had lower baseline caloric intake with 
particularly lower consumption of SFA than subjects without MS resolution. This is in line 
with studies showing the involvement of dietary SFA in the development of cardiovascular 
diseases and supporting the current dietary recommendations to reduce the intake of SFA  [8, 
37] . However, data showing relation between SFA intake and MS are scarce and surprisingly 
controversial, with some reports showing no effect of dietary SFA on chronic diseases  [39] . 
On the other hand, higher dietary SFA were associated with MS development independently 
of BMI, physical activity, and smoking status  [40] . In a cross-sectional study of 4,677 adults, 
Hosseinpour-Niazi et al.  [41] showed that increased SFA intakes were positively associated 
with the prevalence of MS, independently of total dietary fat. It has been suggested that 
augmented alimentary short-chain fatty acids in an animal model could promote conversion 
of SFA to oleate and thus to be a player in MS development  [42] . 
 Another original observation from our study is that plasma levels of PEA were signifi-
cantly related to the MS evolution. Patients who became free of MS at 12 months presented 
lower baseline PEA than patients who still fulfilled the criteria for MS. Lower baseline PEA 
contributed to MS resolution (OR 2.20 (1.08–4.50)) independently of BMI. Among psycho-
logical parameters, there was a relationship between baseline plasma PEA and HAD depression 
score (p = 0.002, R 2  = 0.29). To our best knowledge, these observations have never been 
reported in the literature. On the other hand, the known central nervous system effects of 
cannabinoid type 1 receptor (CB1) blockers (e.g., rimonabant) on mood and depression could 
be mediated by this endocannabinoid congener  [10] .  
 We have previously suggested some potential pathophysiological pathways mediated by 
PEA and OEA, reducing adipose tissue inflammation  [43] . In a prospective cohort of morbidly 
obese patients, massive weight loss induced by gastric bypass was related to a significant 
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increase in all measured endocannabinoids (PEA, OEA, 2-AG, AEA) in subcutaneous adipose 
tissue (SAT). This was accompanied by down-regulation of CB1 receptors and PPAR-alpha 
mRNA expression as well as improvement of inflammatory profile in SAT  [43] . Our group also 
showed recently that the circulating levels of PEA were correlated with coronary function 
parameters  [11] . Thus, plasma PEA levels might represent a potential biomarker of coronary 
dysfunction  [11] and, in the same manner, might be predictive of metabolic evolution asso-
ciated with weight loss. However, data in the literature on PEA or other endocannabinoids in 
relation to MS are scarce. 
 The 12-month follow-up could be considered as a study limitation. A longer follow-up 
would be clinically more meaningful. Long-term follow-up studies on lifestyle interventions 
in obesity are rare. As mentioned in a recent meta-analysis, the mean duration of follow-up 
among 44 studies was 9.3 months  [29] .
 The strengths of our study are the prospective design and the evaluation of multiple 
biological parameters, including plasma endocannabinoid measurement and determination 
of psychological outcomes, eating disorders and QoL in obese patients during a non-dieting 
weight loss program. The majority of studies evaluating weight loss are lifestyle intervention-
based, often with caloric restriction or diet and/or physical activity prescription. In our study, 
we used patient education tailored to patient’s individual needs, motivational interviewing 
as well as combined group sessions and face-to-face appointments with no dietary or physical 
activity prescription at any time during the program. 
 We report for the first time a relationship between plasma PEA and metabolic risk factors 
as well as depression scores, with metabolic evolution being possibly mediated by PEA.
 In conclusion, we could show that a multidisciplinary and patient-educational weight 
loss non-dieting program induces health benefits in the majority of patients. Among patients 
with MS at baseline, 75% have resolved this constellation of cardiometabolic risk factors at 
12 months. In addition to weight loss and improvement of cardiometabolic profile, the weight 
loss program could be beneficial in terms of psychological outcomes, eating disorders, and 
QoL improvement, even in subjects with no weight loss during the program. 
 We report an interesting observation on plasma PEA who might be a potential biomarker 
of metabolic improvements and also severity of depression in obese patients. This should be 
confirmed by larger clinical studies.
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